Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.37 |
| ▸ | MGLL | Q99685 | 2/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | CCNC | P24863 | 1/20 | 0.34 |
| ▸ | CDK8 | P49336 | 1/20 | 0.34 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | CCR2 | P41597 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30012574 | 1.00 | FAAH (0.37) | FAAHP2RX7MGLLEPHX2CCNC | |
| SCHEMBL30013062 | 0.88 | CCR2 (0.35) | PDCD1LG2CD274KCNH2CCR2 | |
| SCHEMBL27147412 | 0.88 | CCR2 (0.35) | PDCD1LG2CD274KCNH2CCR2 | |
| SCHEMBL30012519 | 0.85 | FAAH (0.37) | FAAHP2RX7MGLLEPHX2PDCD1LG2 | |
| SCHEMBL27147404 | 0.85 | FAAH (0.37) | FAAHP2RX7MGLLEPHX2PDCD1LG2 | |
| SCHEMBL25325226 | 0.82 | FAAH (0.38) | FAAHP2RX7MGLLPDCD1LG2CD274 | |
| SCHEMBL30720264 | 0.78 | HRH3 (0.43) | MGLLTRPV4DGAT1KCNH2 | |
| SCHEMBL27149307 | 0.78 | HRH3 (0.43) | MGLLTRPV4DGAT1KCNH2 | |
| SCHEMBL30012490 | 0.77 | MGLL (0.46) | FAAHP2RX7MGLL | |
| SCHEMBL27143260 | 0.77 | MGLL (0.46) | FAAHP2RX7MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199587-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2024-06-20 | — | — | US | claimed |
| EP-4326714-A1 | HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-02-28 | — | — | EP | claimed |
| US-20240199587-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2024-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199587-A1 | HETEROCYCLIC COMPOUNDS | CYP1B1, CYP1A1, CYP4B1 | FAAH 1280/4885P2RX7 81/4885MGLL 4524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.